Bottom line
Is RMEAX a good fund? The bottom line
RMEAX is the Advisor share class of Aspiriant Risk-Managed Equity Allocation Fund, a managed allocation / balanced mutual fund from Aspiriant.
Its expense ratio is 0.95% — about $95 a year on every $10,000 invested, more expensive than 55% of allocation / balanced funds we track.
It returned +17.7% over one year, +9.2% a year over five years, +8.8% a year over ten (as of Dec 31, 2025, per its prospectus).
With $1.4 billion in net assets and 144 holdings, its largest position is GMO Quality Fund (34.5%) and the top 10 make up 73.7% of the portfolio.
What stands out
- 5-year return beat 92% of category peers
- No front-end sales load
What to watch
- Concentrated: top 10 holdings are 73.7% of assets
Updated Nov 19, 2026
What RMEAX invests in
The Aspiriant Risk-Managed Equity Allocation Fund (the Fund or Equity Allocation Fund) seeks to achieve long-term capital appreciation while considering federal tax implications of investment decisions.
Under normal conditions, the Equity Allocation Fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in equity securities. The types of equity securities the Fund may invest in include common stock, preferred stock, and depositary receipts. The Fund also may invest in securities that provide exposure to equity securities ( i.e. , rights, warrants, and investment company shares). The Fund will hold a broad and diverse group of equity securities of companies in countries with developed and emerging markets, which are considered developed or emerging based upon the market definition used by the MSCI ACWI Index (the MSCI Index). The Fund may invest in companies of any market capitalization. The Fund seeks to achieve its investment objective by investing in securities that the Adviser believes offer the most attractive return vs. risk opportunities. The…
From the fund's prospectus (filed Jul 29, 2026).
RMEAX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| RMEAX | +17.7% | +9.2% | +8.8% |
| Allocation / Balanced median | +11.0% | +5.7% | +6.7% |
Source: Fund prospectus, as of Dec 31, 2025
What RMEAX costs
On a $10,000 investment, RMEAX's 0.95% expense ratio costs about $95 a year. The prospectus estimates $1,305 in total costs over 10 years (assuming 5% annual returns). The median allocation / balanced fund charges 0.91%.
RMEAX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | GMO Quality Fund | 34.47% |
| 2 | Schwab Fundamental Emerging Markets Equity ETF | 7.19% |
| 3 | Rief Strategic Partners Fund | 6.44% |
| 4 | Baillie Gifford Emerging Markets Equities Fund | 5.66% |
| 5 | GMO Investments ICAV - GMO Equity Dislocation Investment Fund | 4.32% |
| 6 | AQR Large Cap Defensive Style Fund | 3.83% |
| 7 | Viking Global Equities LP | 3.41% |
| 8 | JPMorgan Prime Money Market Fund | 3.18% |
| 9 | iShares MSCI Global Min Vol Factor ETF | 2.84% |
| 10 | iShares MSCI ACWI ETF | 2.39% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 73.7% of the fund. See all top 25 holdings and asset mix →